Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMS721 in Thrombotic Microangiopathies
NCT02222545Phase 2Completed
- Sponsor
- Omeros Corporation
- Start
- Nov 2014
- Primary completion
- Jan 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of narsoplimab in thrombotic microangiopathy (TMA), atypical hemolytic uremic syndrome (aHUS), thrombotic thrombocytopenic purpura (TTP), sponsored by Omeros Corporation. Started Nov 2014; status: completed.
02
Drugs
narsoplimab
03
Conditions
thrombotic microangiopathy (TMA)atypical hemolytic uremic syndrome (aHUS)thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on NCT02222545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02222545.